149 -12 (74) 2024 - Abdullayev I.A., Ashurov F.Z. - CLINICAL ASPECTS OF COPD IN PATIENTS WITH COVID-19

CLINICAL ASPECTS OF COPD IN PATIENTS WITH COVID-19

Abdullayev I.A. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Ashurov F.Z. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The main task of clinicians when a patient with COPD seeks help is to distinguish an exacerbation of this disease from COVID-19, since there is a similarity in clinical symptoms: cough, fever, intoxication and shortness of breath. The need for further clinical studies on the problem of comorbidity of COPD and COVID-19 is shown, which will allow a detailed study of the mechanisms of mutual aggravation of associated pathology, to clarify the effect of SARS-CoV-2 on the respiratory system and the course of COPD taking into account the phenotype of the disease, to determine effective treatment methods and improve the prognosis of patients with COPD who have had the new coronavirus infection COVID-19.

Key words: comorbidity, COVID-19, chronic obstructive pulmonary disease.

First page

785

Last page

788

For citation:Abdullayev I.A., Ashurov F.Z. - CLINICAL ASPECTS OF COPD IN PATIENTS WITH COVID-19//New Day in Medicine 12(74)2024 785-788 - https://https://newdayworldmedicine.com/en/new_day_medicine/12-74-2024

List of References

  1. Всемирная организация здравоохранения. https://covid19.who.int/table.
  2. Гриневич В.Б., Губонина И.В., Дощицин В.Л. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020 //Кардиоваскулярная терапия и профилактика. 2020;19(4):2630.
  3. Павленко В.И., Кулик Е.Г., Нарышкина С.В., Колосов В.П. Современная противовоспалительная терапия хронической обструктивной болезни легких разного риска обострений. ФГБОУ ВО Амурская ГМА Минздрава России. Благовещенс. 2020. 127с.
  4. Bhutani M, Hernandez P, Bourbeau J, et al. Addressing therapeutic questions to help Canadian health care professionals optimize COPD management for their patients during the COVID-19 pandemic //Canadian Journal of Respiratory Critiacal Care and Sleep Medicine. 2020. In press.
  5. Chalmers J.D., Laska I.F., Franssen F.M.E., et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. //Eur Respir J. 2020;55(6). 2000351. doi: 10.1183/13993003.00351- 2020.
  6. COVID-19 rapid guideline: community- based care of patients with chronic obstructive pulmonary disease (COPD) NICE guideline. www.nice.org.uk/guidance/ ng168. Ссылка активна на 15.02.21.
  7. Daccord C., Touilloux B., Von Garnier C. Asthma and COPD management during the COVID-19 pandemic //Rev. Med. Suisse. 2020;16(692):933-938.
  8. Emami A., Javanmardi F., Pirbonyeh N., Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis //Arch Acad Emerg Med. 2020;24/8(1):e35.
  9. Fang X., Li S., Yu H., et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis //Aging (Albany NY). 2020;12(13):12493-12503. doi: 10.18632/ aging.103579. 10. Geerdink J.X., Simons S.O., Pike R., et al. Differences in systemic adaptive immunity contribute to the ‘frequent exacerbator’ COPD phenotype //Respir Res. 2016;17:140. doi: 10.1186/s12931-016-0456-y.
  10. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2017. www.goldcopd.com Ссылка активна на 15.02.21
  11. Global Initiative for Chronic Obstructive Lung Disease. GOLD COVID-19 Guidance. Available at: GOLD COVID-19 Guidance Global Initiative for Chronic Obstructive Lung Disease GOLD (goldcopd.org). Ссылка активна на 15.02.21
  12. Global Initiative for Chronic Obstructive Lung Disease. 2020 https://goldcopd.org/gold-reports. Ссылка активна на 15.02.21
  13. Goyal P., Choi J.J., Pinheiro L.C. et al. Clinical characteristics of COVID-19 in New York city: Multicenter study //N.Engl. J. Med. 2020;382(24):2372-2374.doi: 10.1056/NEJMc2010419
  14. Guan W.J., Liang W.H., Zhao Y., et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. //Eur Respir J. 2020;14:55(5). P.2000547. doi: 10.1183/13993003.00547-2020.
  15. Halpin D.M.G., Singh D., Hadfield R.M. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective //Eur Respir J. 2020;55(5):2001009. doi: 10.1183/13993003.01009-2020.
  16. Higham A., Mathioudakis A., Vestbo J., Singh D. COVID-19 and COPD: a narrative review of the basic science and clinical outcomes //European Respiratory Review. 2020;29:200199. doi: 10.1183/16000617.0199-2020/
  17. Higham A., Singh D. Increased ACE2 expression in the bronchial epithelium of COPD patients who are overweight. //Obesity (Silver Spring). 2020;28(9):1586-1589. doi: 10.1002/oby.22907.

    file

    download